Solstice Oncology secured $225 million in Series A financing to advance a next-generation CTLA-4 immunotherapy (from Harbour BioMed) into clinical development. The funding aims to support development work through later trials as the company targets CTLA-4-driven responses while differentiating from prior approaches that have struggled in solid tumors.